+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MANKIND

Mankind Pharma Share Price

₹2,503.80 -41.2 (-1.62%)
31.11% Gain from 52W Low

30 Sep, 2026 3:28 PM (IST)

Mankind Pharma live price: ₹2,503.80. It opened at ₹2,545 vs previous close ₹2,545; intraday high/low: ₹2,552/₹2,455. The 50 & 200 DMA stand at ₹2,404.40/₹2,362.90.

Mankind Pharma Performance

  • Today's Low
  • ₹2,455
  • Today's High
  • ₹2,552
  • 52 Week Low
  • ₹1,910
  • 52 Week High
  • ₹2,642
  • Open Price₹2,545
  • Previous Close₹2,545
  • Volume1,362,738
  • 50 DMA₹2,404.40
  • 100 DMA₹2,390.00
  • 200 DMA₹2,362.90

Mankind Pharma Chart

Investment Returns

  • Over 1 Month + 5.07%
  • Over 3 Month + 0.72%
  • Over 6 Month + 22.81%
  • Over 1 Year + 1.7%

Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!

Invest Now

Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 50.6
  • PEG Ratio
  • 6.4
  • Market Cap Cr
  • 103,418
  • P/B Ratio
  • 6.1
  • Average True Range
  • 61.4
  • EPS
  • 49.5
  • Dividend Yield
  • 0
  • MACD Signal
  • 26.1
  • RSI
  • 64.24
  • MFI
  • 79.21

Latest Stock News Updates

Mankind Pharma Ltd - 543904 - Resignation Of Statutory Auditors Of A Material WOS

Please find attached intimation regarding resignation of Statutory Auditors of the Bharat Serums and Vaccines Limited, a matterial wholly owned subsidiary company.

Mankind Pharma Ltd - 543904 - Closure of Trading Window

Please find attached, the intimation of clsoure of the trading window.

Mankind Pharma Ltd - 543904 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report

Mankind Pharma Financials

Mankind Pharma Technicals

EMA & SMA

Current Price
₹2,503.80
-41.2 (-1.62%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹2,405.30
  • 50 Day
  • ₹2,404.40
  • 100 Day
  • ₹2,390.00
  • 200 Day
  • ₹2,362.90

Resistance and Support

2503.6 Pivot Speed
  • R3 2,712.60
  • R2 2,635.80
  • R1 2,590.40
  • S1 2,468.20
  • S2 2,391.40
  • S3 2,346.00

Mankind Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-30 Quarterly Results
2026-05-19 Audited Results
2026-02-03 Quarterly Results
2025-11-06 Quarterly Results
2025-07-31 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-08-08 INTERIM Rs.1.00 per share(100%)Interim Dividend
View Mankind Pharma Dividend History Arrow

Mankind Pharma F&O

Mankind Pharma Shareholding Pattern

72.63%
10.87%
9.45%
4.52%
2.53%

About Mankind Pharma

Mankind Pharma engaged in the manufacturing and trading of pharmaceuticals and health care products. The Company has three manufacturing facilities at Paonta Sahib in the state of Himachal Pradesh, one manufacturing facility in state of Sikkim, two manufacturing facilities in state of Rajasthan, one manufacturing facility in state of Andhra Pradesh, three in-house research and development centres in the state of Haryana and one research and development centre in the state of Maharashtra to carry out research in pharmaceutical products. View More
  • NSE Symbol
  • MANKIND
  • BSE Symbol
  • 543904
  • ISIN
  • INE634S01028

Similar Stocks to Mankind Pharma

Mankind Pharma FAQs

Mankind Pharma share price is ₹2,503 As on 30 September, 2026 | 15:36

The Market Cap of Mankind Pharma is ₹103418.2 Cr As on 30 September, 2026 | 15:36

The P/E ratio of Mankind Pharma is 50.6 As on 30 September, 2026 | 15:36

The PB ratio of Mankind Pharma is 6.1 As on 30 September, 2026 | 15:36

The 52 week High & Low of Mankind Pharma is ₹2642/₹1909.7 respectively As on 30 September, 2026 | 15:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23